Drug Trial Radar · NCT00405418
Lantus Versus Levemir Treat-To-Target
Last checked: Nov 20, 2026Latest source record: Sep 15, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
973
Actual
Start
Nov 2006
Primary completion
Jun 2008
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 30, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary objective: To demonstrate the non-inferiority of insulin glargine in comparison to insulin detemir in term of percentage of patients who reach the target of HbA1c \< 7% at the end of the treatment period and do not experience symptomatic hypoglycemia, confirmed by plasma glucose (PG) ≤ 56 mg/dL (3.1 mmol/L) Secondary objectives: * To compare between the 2 treatment groups, the percentage of patients who reach the target of HbA1c \< 7% and \< 6.5% at the end of the treatment period * To compare the changes in HbA1c and fasting plasma glucose (FPG) * To compare the evolution of blood glucose profiles * To compare the day to day FPG variability, the insulin doses * To determine in each treatment group the biochemical and patient-related determinants of failure to reach HbA1c targets * To compare the overall incidence and rate of symptomatic hypoglycemia and nocturnal symptomatic hypoglycemia confirmed by PG ≤ 56 mg/dL (3.1 mmol/L) * To compare over the treatment period, the overall incidence and rate of symptomatic hypoglycemia and symptomatic nocturnal hypoglycemia (with PG ≤ 70 mg/dL \[3.9 mmol/L\]), of symptomatic day-time hypoglycemia (with PG ≤ 70 mg/dL and with PG ≤ 56 mg/dL), of severe hypoglycemia, of asymptomatic hypoglycemia with PG ≤ 56 mg/dL * To compare the overall safety: incidence of adverse events (including serious hypoglycemia and local tolerance at injection site), change in body weight, in waist circumference and in waist / hip ratio * To assess the quality of life and treatment satisfaction
Conditions
- Diabetes Mellitus, Type 2
Interventions
Insulin glargineDrug
Subcutaneous injection, once a day in the evening
Insulin DetemirDrug
Subcutaneous injection, twice a day at breakfast and before dinner
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1c recordedTime frame: At baseline, week 12 and week 24
- Self-monitored fasting BG in both treatment arms and pre-dinner BG in detemir armTime frame: On the 4 consecutive days before each visit
- Self-monitored BG values from 8-point 24-hour profile recorded on 2 consecutive daysTime frame: Within the week prior to baseline, week 12 and week 24
- Episodes of hypoglycemia (symptomatic, total and categorized as day-time/nocturnal, severe or asymptomatic)Time frame: All across the study
- Self-monitored BG values whenever patient experiences symptoms possibly related to hypoglycemia.Time frame: All across the study
Locations
20 sites in 20 countries. Site status is shown where the registry gives one.
Sanofi-Aventis
North Ryde, Australia
Sanofi-Aventis
São Paulo, Brazil
Sanofi-Aventis
Laval, Canada
Sanofi-Aventis
Hoersholm, Denmark
Sanofi-Aventis
Helsinki, Finland
Sanofi-Aventis
Berlin, Germany
Sanofi-Aventis
Mumbai, India
Sanofi-Aventis
Dublin, Ireland
Sanofi-Aventis
Gouda, Netherlands
Sanofi-Aventis
Porto Salvo, Portugal
Sanofi-Aventis
Bucharest, Romania
Sanofi-Aventis
Moscow, Russia
Sanofi-Aventis
Belgrade, Serbia
Sanofi-Aventis
Seoul, South Korea
Sanofi-Aventis
Barcelona, Spain
Sanofi-Aventis
Stockholm, Sweden
Sanofi-Aventis
Meyrin, Switzerland
Sanofi-Aventis
Taipei, Taiwan
Sanofi-Aventis
Istanbul, Turkey (Türkiye)
Sanofi-Aventis
Guildford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.